Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Anal Cancer Metastatic × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 240 Neoplasms 153 Breast Neoplasms 152 Colorectal Neoplasms 143 Melanoma 113 Prostatic Neoplasms 110 Neoplasm Metastasis 110 Ovarian Neoplasms 108 Leukemia, Myeloid, Acute 106 Recurrence 98 Multiple Myeloma 95 Pancreatic Neoplasms 94 Squamous Cell Carcinoma of Head and Neck 85 Lung Neoplasms 85 Stomach Neoplasms 84 Lymphoma 77 Lymphoma, Non-Hodgkin 75 Triple Negative Breast Neoplasms 73 Glioblastoma 73 Lymphoma, Large B-Cell, Diffuse 63 Carcinoma, Renal Cell 63 Precursor Cell Lymphoblastic Leukemia-Lymphoma 62 Endometrial Neoplasms 56 Advanced Solid Tumor 55 Leukemia, Lymphocytic, Chronic, B-Cell 50 Leukemia 49 Carcinoma, Hepatocellular 47 Uterine Cervical Neoplasms 46 Myelodysplastic Syndromes 46 Head and Neck Neoplasms 46

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07280377 2025-12-12

GOBLET

Oncolytics Biotech

Phase 1/2 Recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡